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Here we present a male patient with acute myeloid leukemia (AML) initially diagnosed as M5 and with karyotype
46,XY. After induction therapy, he underwent a HLA-matched allogeneic hematopoietic stem cell transplantation,
and six years later he relapsed as AML M1 with an abnormal karyotype //47,XX,+10[2]/47,XX,+11[3]/48,XX,+10,+11
[2]/46,XX[13]. Based on this, we tested the possibility of donor cell origin by FISH and molecular STR analysis. We
found no evidence of Y chromosome presence by FISH and STR analysis consistent with the success of the allogeneic
hematopoietic stem cell transplantation from the female donor. FISH studies confirmed trisomies and no evidence of
MLL translocation either p53 or ATM deletion. Additionally 28 fusion common leukemia transcripts were evaluated by
multiplex reverse transcriptase-polymerase chain reaction assay and were not rearranged. STR analysis showed a
complete donor chimerism. Thus, donor cell leukemia (DCL) was concluded, being essential the use of cytological and
molecular approaches. Pediatric DCL is uncommon, our patient seems to be the sixth case and additionally it presented
a late donor cell leukemia appearance. Different extrinsic and intrinsic mechanisms have been considered to explain
this uncommon finding as well as the implications to the patient.
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Acute myeloid leukemia (AML) is a clinically and genetic-
ally heterogeneous hematological disease. Patient age,
cytogenetic and minimal residual disease after induction
therapy, play a major role in the classification and progno-
sis of AML, leading to stratification in risk categories [1,2].
Allogeneic hematopoietic stem cell transplantation
(alloHSCT), results in superior disease-free survival and
overall survival (OS) rates in patients with intermediate
and high risk AML. Nowadays, many progresses have* Correspondence: alcoronar@gmail.com
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article, unless otherwise stated.been made concerning donor selection, reduction of
myeloablative conditioning and management of the im-
munologic graft-versus-leukemia effect that all together
provides a therapeutic effectiveness. Nevertheless all
these advances, leukemia relapse remains the main prob-
lem that reduces the cure rates after alloHSCT [3]. A re-
lapse is diagnosed when patient-derived cells survived
the myeloablative therapy and the original leukemic cell
reappears at any site in the body. Most of them occur
during the first year of treatment, late relapse is not
common and occurs after two years of treatment. Sec-
ondary leukemia may develop after successful treatment
when non-biologically related clone to original cells arise
and appears as hematologic neoplasia. Secondary leukemia
must be differentiated from late relapse which descend
from the same original cell that originated the primary
malignancy [4]. Secondary leukemia can develop in a
patient-derived clone, but in some rare cases, arise from
engrafted donor cells [5], and becomes a new disordered Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in 1971 by Fialkow and colleagues and through 2011,
more than 80 cases have been reported in the literature
[6-8]. Most of the reported secondary AML arise after an
autologous transplantation, and not allogeneic transplant-
ation [4], this might be due to the lack of graft versus
leukemia effect [5]. Relapse is observed in at least 33% of
the transplanted patients with AML/myelodysplastic syn-
drome and Wiseman et al. [6], suggested that up to 5% of
all post-transplant leukemia correspond to DCL. Different
mechanisms have been proposed to explain the etiology of
DCL [9], however it remains to be established if the ori-
ginal mechanism whether occurred in donor or receptor
cells. Most of the reported cases arise from adult patients.
Pediatric DCL is uncommon, our patient seems to be the
sixth reported case presented with a late appearance after
68 months. The aim of the present report is to present a
male boy with AML-M5 at diagnosis successfully treated
with HLA-matched sibling alloHSCT who developed a
second AML-M1 in cells of donor origin.
Case presentation
A 9-year-old boy was diagnosed with AML-M5 by French
American British (FAB) classification in December 2005.
The bone marrow aspirate showed 100% blasts and cere-
brospinal fluid was positive for leukemic blasts. Cytogen-
etic analysis showed a normal karyotype 46,XY. Flow
cytometry immunophenotype was positive to CD13,
CD33, CD34, CD38, HLA-DR, MPO, CD14, and CD11.
The treatment consisted of two cycles of cytarabine
1000 mg/m2 three weeks apart. Minimal residual disease
was positive at day 14 and two more induction cycles were
given to achieve complete remission. He received consoli-
dation chemotherapy and was successfully treated with
alloHSCT transplantation from his HLA-identical sister.
Conditioning regimen consisted on busulfan 16 doses
of 1 mg/kg/PO every 6 hours and cyclophosphamide
120 mg/kg. Sixty-eight months after transplant the patient
presented febrile with neutropenia and thrombocytopenia,
bone marrow aspirates showed 98% of blasts consistent
with AML M1 (Figure 1a-b), which was compatible with
the immunophenotype.Figure 1 Bone marrow aspirates. a) At diagnosis as LMA M5. b) At relapThe patient died after two induction cycles with the
National Myeloid Protocol which consist of 7 doses of
cytarabine 100 mg/m2, 3 doses of daunorrubicin 50 mg/m2
and five days with central nervous system prophylaxis with
intrathecal chemotherapy (methotrexate/cytarabine/hydro-
cortisone). Minimal residual disease before the second cycle
was 8% and the patient died by septic shock 7 days after he
finished the second cycle.
The bone marrow morphology of M5 at diagnosis was
confirmed with immunophenotype, CD13, CD33, CD34,
CD38, HLA-DR, MPO, CD14, and CD11. At relapse, the
morphology and immunophenotype positive for HLA-
DR, CD117, MPO, CD38, CD34, CD45, CD15 (mild)
and CD13, concluded AML M1. Additional studies were
performed on relapse as follows.
Discussion and conclusions
Here we present a case of a DCL AML-M1 formerly diag-
nosed as AML-M5 in a pediatric male patient successfully
treated with a HLA-matched alloHSCT. The karyotype,
FISH and STR analysis evidenced a completely new
disease on female donor cells, indicating a successful
transplant and implying a different and more complex ap-
proach of the case.
DCL is a rare but well-recognized disease that affects
patients treated with hematopoietic cells transplantation
as a late complication [6]. This patients develop a sec-
ondary leukemia from cells derived from the donor and
the diagnosis depends on the ability to accurately iden-
tify the donor origin of the leukemic cells [8]. In these
case we conclude that our patient acquired a secondary
leukemia derived from his sister donor cells since FISH
analysis showed 100% of XX centromeres of the ana-
lyzed leukocytes. Molecular testing by STR analysis
demonstrated that sample from bone marrow and mu-
cosal swap from the patient had different DNA.
Abnormal cytogenetics has been found in 72% of cases
with DCL/myelodisplastic neoplasms, being the most
common aberrations chromosome 7 monosomy or 7q
deletion (29%), occurring always in myeloid neoplasms
(AML or myelodysplastic syndrome (MDS) so far there is
no evidence of a structural or numerical aberrationse as LMA M1.
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approach to search for DCL [6], as occurred in our pa-
tient. Isolated trisomy 10 is an extremely uncommon
event, in pediatric leukemia. In a review, Yuan et al., re-
ported just 3 pediatric and 20 adults AML patients with
trisomy 10 and their impact in disease progression and
prognosis remains unclear [11]. Despite the few cases
with +10, the most have been observed in AML M1 pa-
tients [12]. Trisomy 11 is a rare event associated with poor
prognosis, Alseraye et al. [1], reported a group of 18 pa-
tients with trisomy 11 that included de novo AML cases,
patients with a history of MDS and patients with a pro-
gressive clinical course of refractory or relapsed disease.
Suzuki et al. [12], found a low incidence of trisomy 10
(0.28%) and trisomy 11 (0.47%) as a sole abnormality from
1074 adult AML patients. Morphology of 55% of the
patients was classified as AML-M1 and the OS was
5 months. We did not find a case report with both 10 and
11 trisomies in the same patient, in concordance with
Alseraye et al. [1], our patient classified as AML-M1 and
trisomy 11, also presented an unfortunate ending since he
died before acquire remission after 2 months of diagnosis
from the DCL. The initial and post-transplant karyotypes
suggest that the original leukemic cell population was dif-
ferent from the new one. Furthermore, TEL-AML1 fusion
gene, which has been implicated in late relapses [13], was
not translocated in our patient [13]. Our case did not have
structural abnormalities and observed numerical aberra-
tions seem to be associated to the observed leukemia, at
present no prognosis abnormality has been defined.
Previous reports have shown that alkylating agents,
and topoisomerasa II inhibitors are a risk factor to
develop secondary AML [14]. Patients treated with
topoisomerasa-II inhibitors typically results with MLL
(11q23) [15], or less common RUNX1 gene (21q22)
translocations. Alkylating agents presents in 90% of the
cases loss of part or complete chromosomes 5 and/or 7
[14,16]. Our patient was treated with doxorubicin a
topoisomerasa-II inhibitor and cyclophosphamide, a well
known alkylating agent [14] and due to the treatment re-
ceived, the patient was in the higher risk to develop a
secondary leukemia however, we did not find any re-
arrangement in MLL gene or deletion in chromosome 5Table 1 Reported pediatric cases of donor cell leukemia and
Age 1st disease 2nd disease Months after
4 AML AML 23
12 CML ALL 15
NA* T-ALL B-ALL NA
16 AML B-ALL 12
3 AML M5 AML 14.5
16 AML M5 AML M1 68
NA* = Not Available.and 7. Then, we may no support in our patient chemo-
therapy related DCL.
Wiseman [6], reported that 75% of DCL are different
from the original disease and that arise as AML in 53%
of cases 25% as ALL and 20% as MDS. Our patient was
formerly diagnosed with AML-M5 and as with AML-
M1 in the second leukemia, maintaining the same
lineage but in a different maturation stage. We found in
the literature, 5 pediatrics cases of DCL. In 3/5, they re-
lapsed with different lineage and in contrast with the
adult DCL which most of them originates in an AML or
MDS, in the pediatric patients 50% of the DCL are ALL
and 50% AML. In previous reports of pediatrics patients,
the maximum period of time after transplant and DCL
was 23 months, in our case the patient relapsed after
68 months. The pediatric DCL cases are presented in
Table 1.
Different mechanisms have been proposed to explain
the etiology of DCL. Extrinsic factors focus on chemo-
therapy and radiation-induced stromal abnormalities
[6,8,21]. Intrinsic factors may be related to the donor,
such as leukemia previously present in donor cells or
leukemic predisposition [6]. On the other hand intrinsic
factors can be related to the recipient, including im-
paired immune function [8], transformation of donor
cells by antigenic stimulation through host tissue, onco-
gene transfection from abnormal to normal cells [9],
replication stress, and host microenvironment [7,22].
Not all cases that develop DCL arise from previous ma-
lignant diseases [9], suggesting alternative explanations
to stromal abnormalities and oncogene transfection the-
ories [9,10]. Any specific conditioning, graft manipula-
tion and graft-versus-host disease prophylaxis has been
identified as risk factors for DCL [23].
Additionally to numerical chromosomal abnormalities,
we were not able to detect structural cytogenetic and
molecular abnormalities in donor cells. Related to this,
the donor sister has been maintained without clinical evi-
dence of hematologic disorder, and apparently healthy. Be-
sides, the observation of normal tested tumor suppressor
genes, fusion genes absence, and MLL integrity, support
that more host microenvironment conditions that donor
cells may be implicated. Despite the microenvironmentalpresent case






BMT Sister Present case
Figure 2 Karyograms from the patient at relapse. a) Normal metaphase. b) Trisomy of chromosome 10. c) Trisomy of chromosome 11.
d) Trisomies of chromosomes 10 and 11.
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needed to confirm if the original mechanism occurred in
donor or receptor cells [9,21,24]. A multifactorial compo-
nent may be involved, and considering that from 5/6
pediatric DCL the donor has been related, there could be
a familial predisposing involvement.Figure 3 Interphase FISH studies. a) XY probe (X spectrum green and Y
(spectrum green) probe supports the trisomy of chromosome 10. c) No dis
third signal corresponds to the extra chromosome 11. d) Simultaneous p53
deletion of any suppressor gene, but the third signal of ATM agrees with t
for the presence of the fusion gene.In summary, pediatric DCL might be a less heteroge-
neous group that those observed in adults. To identify
the presence of DCL is essential the use of cytological
and molecular approaches which eliminate the possibil-
ity of a relapse from the original clone. Nevertheless the
DCL in our patient has been well supported, the directspectrum red) shows the presence of donor female cells. b) CEP 10
ruption of MLL gene was observed using a MLL break apart probe; the
(spectrum green) and ATM (spectrum Orange) test, showed no
he trisomy 11. e) Tel-AML1 (red/green signal) evaluation was negative
Table 2 Post-transplant STR analysis from the patient mucosal swap, bone marrow, and blood from the donor
Marker Patient’s mucosal swap at relapse Patient’s bone marrow at relapse Donor’s blood
D8S1179 10 10 10 10 10 10
D21S11 28 30 28 30 28 30
D7S820 10 12 10 12 10 12
CSF1PO* 9 12 9 10 9 10
D3S1358* 15 17 17 17 17 17
TH01* 7 7 8 8 8 8
D13S317* 10 13 10 12 10 12
D16S539* 10 12 10 10 10 10
D19S433 14.2 15 14.2 15 14.2 15
vWA* 16 16 16 18 16 18
TPOX* 8 12 11 11 11 11
D18S51 17 18 17 18 17 18
DS5818* 7 12 12 12 12 12
FGA* 24 25 25 26 25 26
Amelogenina X Y X X X X
* = informative alleles.
Table 3 Involved translocation genes studied by nested multiplex PCR
Traslocation* Genes Traslocation Genes Traslocation Genes
t(X;11)(q13;q23) MLL (11q23) TAL1 (deleción) STIL (1p32) t(9;22)(q34;q11) BCR (22q11)
FOZO4 (Xq13.1) TAL1 (1p32) ABL1 (9q34.1)
t(6;11)(q27;q23) MLL (11q23) t(8;21)(q22;q22) RUNX1 (21q22.3) t(9;12)(q34;p13) ETV6 (12p13)
MLLT4 (6q27) RUNX1T1 (8q22) ABL1 (9q34.1)
t(11;19)(q23;p13.1) MLL (11q23) t(3;21)(q26;q22) RUNX1 (21q22.3) t(5;12)(q33;p13) ETV6 (12p13)
ELL (19p13.1) MDS1 (3q26) PDGFRB (5q33)
t(10;11)(p12;q23) MLL (11q23) t(16;21)(p11;q22) FUS (16p11.2) t(12;22)(p13;q11-12) ETV6 (12p13)
MLLT10(10P12) ERG (21q22.3) MN1 (22q12.1)
t(1;11)(p32;q23) MLL (11q23) t(15;17)(q22;q12) PML (15q22) t(6;9)(p23;q34) DEK (6p23)
EPS15 (1p32) RARA (17q12) NUP214 (9q34)
t(11;17)(q23;q12-21) MLL (11q23) t(9;22)(q34;q11) BCR (22q11) t(9;9)(q34;q34) SET (9q34)
MLLT6 (17q21) ABL1 (9q34.1) NUP214 (9q34)
t(11;19)(q23;p13.3) MLL (11q23) t(4;11)(q21;q23) MLL (11q23) inv(16)(p13;q22) CBFB (16q22.1)
MLLT1 (19P13.3) AFF1 (4q21.3) MYH11 (16p13.11
t(10;11)(p12;q23) MLL (11q23) t(10;11)(p12;q23) MLL (11q23) t(3;21)(q26;q22) RUNX1 (21q22.3)
MLLT10 (10p12) MLLT10 (10p12) EAP (3q26)
t(9;11)(p22;q23) MLL (11q23) t(11;19)(q23;P13.3) MLL (11q23) t(11;17)(q23;q12-21) ZBTB16 (11q23)
MLLT3 (9p22) MLLT1 (19p13.3) RARA (17q12)
t(1;19)(q23;p13) TCF3 (19p13.3) t(9;11)(p22;q23) MLL (11q23) t(3;21)(q26;q22) RUNX1 (21q22.3)
PBX1 (1q23.3) MLLT3 (9p22) EVI1 (3q26)
t(17;19)(q22;p13) TCF3 (19p13.3) t(1;11)(q21;q23) MLL (11q23) t(15;17)(q22;q12) PML (15q22)
HLF (17q22) MLLT11 (1q21) RARA (17q12)
t(12;21)(p13;q22) ETV6 (12p13) inv(16)(p13;q22) CBFB (16q22.1) t(3;5)(q25.1;q35) NPM1 (5q22)
RUNX1 (21q22.3) MYH11 (16p13.11 MLF1 (3q25.1)
* = All the translocations tested were negative in our patient.
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Cytogenetic analysis performed on bone marrow sample
using standard culture methods and GTW banding
showed an abnormal female karyotype: //47,XX,+10[2]/47,
XX,+11[3]/48,XX,+10,+11[2]/46,XX[13] (Figure 2a-d).
FISH studies
To test for the presence of additional 10 and 11 chromo-
somes, we performed Fluorescence in situ hybridization
(FISH), on bone marrow samples using centromere 10
(CEP 10 green, KBI-20010G, Kreatech), and MLL (LSI
dual dolor break apart, 05 J90-001, Abbott Molecular)
FISH probes. The results were reported according to
ISCN 2013 as follows. Centromere 10: //nucish(D10Z1x3)
[92/200]. MLL: //nuc ish(5′MLL con 3′MLLx3)[150/200].
Cep 10 and MLL showed three copies, agreeing with the
trisomy 10 and 11 found in karyotype (Figure 2b,c).
The sex chromosomes status was tested using centro-
meres X/Y (SE DXZ1 green/SE DXZ1 red, KBI-20030,
Kreatech) FISH probe, resulting as follows: //nucish
(DXZ1x2)[192/200]. The presence of a pair of centromere
X sequences supports a donor cell origin, (Figure 3a).
Complimentary FISH probes on bone marrow samples
using TEL/AML1(LSI TEL SG/LSI AML1 SO, 05 J62-
001, Abbott Molecular) and TP53/ATM (LSI TP53 SG/
LSI ATM SO, 05 J83-001, Abbott Molecular), resulted in
normal fluorescence patterns, although ATM exhibited
an additional signal showing the extra 11 chromosome
(Figure 3d,e).
STR studies. Microsatellite short tandem repeat (STR)
analysis were performed for 15 loci (CSF1PO, D2S1338,
D3S1358, D5S818, D7S820, D8S1179, D13S317, D16S539,
D18S51, D19S433, D21S11, FGA, TH01, TPOX, and
vWA) and sex determination by amelogenin (AmpFLSTR
Identifiler, 4322288, Life Technologies) on genomic DNA
from bone marrow and mucosal swap of the post-
transplant patient and in blood from the donor (Table 2).
From the 15 microsatellite markers tested, differences
were found between the oral mucosal and blood from the
patient in the 9/14 informative alleles and Y chromosome
was not detected concluding that the AML was derived
from the donor cells.
Multiplex PCR studies
To detect the most common fusion transcripts found in
AML and ALL, we performed nested multiplex reverse
transcriptase-polymerase chain reaction assay (HemaVision,
HV01-28 N, DNA Technology A/S). The 28 fusion tran-
scripts evaluated are shown in Table 3. Our patient wasnegative for the amplification of all of them, while the en-
dogenous controls were positive in every PCR reaction.
Consent
Written informed consent was obtained from the patient's
parents for publication of this Case report and any accom-
panying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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